Montreal Heart Institute
Montreal, Quebec, H1T 1C8, Canada
NCT Number: NCT06332456
The aim of this study is to demonstrate that positron emission tomography imaging with Rubidium-82 (radioactive tracer) can non-invasively detect and quantify changes in renal blood flow (renal perfusion) and renal vascular resistance in both healthy subjects and patients with renal insufficiency. Ultimately, the results of this study will contribute to a better understanding of the role of positron emission imaging in the evaluation of patients with renal diseases.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Montreal, Quebec, H1T 1C8, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Control Group
CKD Group
Exclusion criteria
Control Group
CKD Group
Time frame: 1 day
Average difference of RBF between healthy controls and CKD participants
Time frame: 1 day
Average difference of RVR between healthy controls and CKD participants
Time frame: Up to 4 weeks
Correlation coefficient between RBF vs echographic measurements of renal RI
Time frame: 1 day
Coefficient of repeatability, coefficient of variation, and correlation between repeated measurements
Matthieu Pelletier-Galarneau, MD MSc
Other
Assessment of Renal Microcirculation With Rubidium Positron Emission Tomography: A Proof-of-Concept Study
Acronym: RESIST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.